Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks).


Options:
A: Arm Label: Vildagliptin & metformin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin | Arm Label: Glibenclamide & metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glibenclamide, Drug: Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin & metformin | Intervention Type: DRUG; Name: Glibenclamide; Assigned to Arm(s): Glibenclamide & metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glibenclamide & metformin, Vildagliptin & metformin
B: Arm Label: BI 10773 dose plus metformin; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Glimepiride 1-4 mg plus metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 dose plus metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride 1-4 mg plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Glimepiride 1-4 mg plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 dose plus metformin
C: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin, Drug: placebo | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Met Mono; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: placebo | Arm Label: Met + Glim; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met + Glim, Met Mono | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Met + Glim | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met Mono | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Met + Glim, Met Mono | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met
D: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride

Answer: C